TheraCryf Expands Pipeline with Chronos Acquisition

Evgen Pharma (GB:TCF) has released an update.

TheraCryf plc, a clinical-stage drug development company, has expanded its R&D portfolio with the acquisition of Chronos Therapeutics, tripling its pipeline and enhancing monetization opportunities. The company reported a post-tax loss of £1.1m for the half-year, with a cash balance of £1.2m, reflecting ongoing investments in promising oncology and neuropsychiatry programs. Recent advancements include promising data on their lead asset SFX-01 and a new European patent grant for their OX-1 antagonist, positioning TheraCryf for potential future growth.

For further insights into GB:TCF stock, check out TipRanks’ Stock Analysis page.